RTP Mobile Logo
Select Publications

Burger RA et al. Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer. SGO 2022;Abstract 588.

Gao Q et al. Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study. SGO 2022;Abstract 41.

Hardesty MM et al. OVARIO, a phase 2 study of niraparib + bevacizumab in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab: Updated analysis. SGO 2022;Abstract 40.

Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.

Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA4.

Moore K et al. Evolution of the ovarian cancer treatment paradigm, including maintenance treatment, in the US and Europe: A real-world chart review analysis (2017–2020). SGO 2022;Abstract 28.

Moore KN et al. MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR-alpha) expression. SGO 2022;Abstract 297.

Mulvey B et al. Efficacy of combining tumor treating fields (TTFields) with a PARP inhibitor in ovarian cell lines. SGO 2022;Abstract 300.5.

Okamoto A et al. A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort. SGO 2022;Abstract 329.

Penson RT et al. Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer. SGO 2022;Abstract 26.

Richardson DL et al. Updated results from the phase 1 expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 76.

Richardson DL et al. UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. SGO 2022;Abstract 585.

Rodriguez I et al. Identifying BRCA wild-type ovarian cancers with a homologous recombination deficiency phenotype. SGO 2022;Abstract 100.

Saevets V et al. MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy. SGO 2022;Abstract 334.